Abstract
Purpose
To evaluate the effect of orbital decompression surgery on quality of life in thyroid-associated ophthalmopathy (TAO) patients.
Methods
From August 2014 to December 2015, 80 patients diagnosed with TAO at our clinic were retrospectively analyzed. The patients were divided into 2 groups: 30 patients who underwent orbital decompression surgery and 50 patients who did not receive surgery. The Korean version of the Grave's ophthalmopathy specific quality of life (GO-QoL) questionnaire was completed by all patients. We compared questionnaire scores between groups and analyzed demographic and clinical factors affecting change in GO-QoL.
Results
The patients who underwent orbital decompression had lower mean GO-QoL score for appearance in comparison with patients without orbital decompression (p < 0.001). The mean GO-QoL score for appearance was increased from 28.8 ± 17.1 to 51.5 ± 18.8 after orbital decompression (p = 0.024). The mean GO-QoL score for visual function was not different between the patients who did not receive surgery and the orbital decompression group. The mean GO-QoL score for visual function was not changed after orbital decompression. There was a significant relation between postoperative proptosis degree and change in GO-QoL score for appearance after orbital decompression.
References
1. Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev. 1993; 14:747–93.
2. Bahn RS. Understanding the immunology of Graves' ophthalmopathy. Is it an autoimmune disease? Endocrinol Metab Clin North Am. 2000; 29:287–96. vi.
3. Choi YJ, Lim HT, Lee SJ, et al. Assessing Graves' ophthalmop-athy-specific quality of life in Korean patients. Eye (Lond). 2012; 26:544–51.
4. Son BJ, Lee SY, Yoon JS. Evaluation of thyroid eye disease: abdominal-of-life questionnaire (TED-QOL) in Korean patients. Can J Ophthalmol. 2014; 49:167–73.
5. Lee H, Roh HS, Yoon JS, Lee SY. Assessment of quality of life and depression in Korean patients with Graves' ophthalmopathy. Korean J Ophthalmol. 2010; 24:65–72.
6. Bartalena L, Marocci C, Bogazzi F, et al. Glucocorticoid therapy of Graves' ophthalmopathy. Exp Clin Endocrinol. 1991; 97:320–7.
7. Lyons CJ, Rootman J. Orbital decompression for disfiguring exophthalmos in thyroid orbitopathy. Ophthalmology. 1994; 101:223–30.
8. Fatourechi V, Garrity JA, Bartley GB, et al. Graves ophthalmopathy. Results of transantral orbital decompression performed primarily for cosmetic indications. Ophthalmology. 1994; 101:938–42.
9. Wickwar S, McBain H, Ezra DG, et al. The psychosocial and abdominal outcomes of orbital decompression surgery for thyroid eye abdominal and predictors of change in quality of life. Ophthalmology. 2015; 122:2568–76.e1.
10. Terwee CB, Dekker FW, Mourits MP, et al. Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin Endocrinol (Oxf). 2001; 54:391–8.
11. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf). 1997; 47:9–14.
12. Terwee CB, Gerding MN, Dekker FW, et al. Test-retest reliability of the GO-QOL: a disease-specific quality of life questionnaire for patients with Graves' ophthalmopathy. J Clin Epidemiol. 1999; 52:875–84.
13. Achtsidis V, Tentolouris N, Theodoropoulou S, et al. Dry eye in Graves ophthalmopathy: correlation with corneal hypoesthesia. Eur J Ophthalmol. 2013; 23:473–9.
14. Abràmoff MD, Kalmann R, de Graaf ME, et al. Rectus extraocular muscle paths and decompression surgery for Graves orbitopathy: mechanism of motility disturbances. Invest Ophthalmol Vis Sci. 2002; 43:300–7.
15. Garrity JA, Fatourechi V, Bergstralh EJ, et al. Results of transantral orbital decompression in 428 patients with severe Graves' ophthalmopathy. Am J Ophthalmol. 1993; 116:533–47.
16. Terwee CB, Gerding MN, Dekker FW, et al. Development of a abdominal specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL. Br J Ophthalmol. 1998; 82:773–9.
17. Soeters MR, van Zeijl CJ, Boelen A, et al. Optimal management of Graves orbitopathy: a multidisciplinary approach. Neth J Med. 2011; 69:302–8.
Table 1.
No-surgery group | Decompression group | p-value | |
---|---|---|---|
Number | 50 | 30 | |
Sex (male/female) | 18/32 | 12/18 | 0.721* |
Age (years) | 34.7 ± 12.4 (16–63) | 33.8 ± 11.0 (18–60) | 0.693‡ |
Family history of thyroid disease (n, %) | 17 (34) | 13 (43.3) | 0.944* |
Smoker (n, %) | 9 (18) | 4 (13.3) | 0.757† |
Duration of eye symptoms (months) | 34.5 ± 40.5 (6–144) | 41.9 ± 56.5 (10–180) | 0.207‡ |
Clinical activity score | 2.2 ± 1.1 | 2.5 ± 1.1 | 0.177‡ |
Exophthalmos | 18.8 ± 2.2 | 19.8 ± 2.5 | 0.521‡ |
Compression neuropathy (n, %) | 5 (10) | 2 (6.7) | 0.706† |